![](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/GC-Healthcare.png\"\/)
<\/p>\n <\/p>\n
GrowthCap is pleased to announce The Top Healthcare Investors of 2026.<\/p>\n
As one of the largest and most vital industries globally, healthcare\u2014including healthcare technology, services, and related sub-sectors\u2014remains a central focus and high-performing area for leading growth investment firms.<\/p>\n
Over the years, we have closely followed healthcare investors and recognize the depth of experience and specialized expertise required to succeed in this complex and rapidly evolving sector. Now in our sixth year of this awards process, we evaluate both the breadth of each investor\u2019s track record and the impact of their more recent achievements.<\/p>\n
This year\u2019s awardees stand out as exceptional partners to their portfolio companies, limited partner investors, and firm colleagues, among others. They demonstrate a distinct ability to identify solid investment opportunities and apply their expertise, insight, and commitment to drive successful outcomes.<\/p>\n
From healthcare software and AI-powered solutions to biotechnology, medical devices, digital health, tech-enabled services, and beyond, these investors are at the forefront of innovation\u2014shaping how patient care is delivered, experienced, and managed.<\/p>\n
Our evaluation process is informed by nomination submissions, feedback from colleagues, peers, and portfolio company leaders, and supplemented by in-depth research. In particular, we assess each nominee\u2019s investment history, leadership, and the tangible impact they have had on the companies and teams they work with.<\/p>\n
While we could not recognize each impressive nominee who participated, we would like to acknowledge their accomplishments and look forward to following their careers in the years ahead.<\/p>\n
Please join us in celebrating the achievements of The Top Healthcare Investors of 2026.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Jeff Haywood<\/p>\n
Firm: Spectrum Equity
Title: Managing Director and Co-Head of Spectrum Healthcare Investing<\/p>\n
\u00a0<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Jeff-Haywood-Spectrum-Website.png\"\/)
<\/p>\n
Jeff Haywood has co-led Spectrum Equity<\/a>\u2018s healthcare investing with Steve LeSieur since 2015, focusing on high-growth software and data services companies across the healthcare continuum.<\/p>\n Jeff currently serves on the boards of Definitive Healthcare (NASDAQ: DH), RxVantage, and VBA. He led Spectrum\u2019s investment in PWNHealth and its subsequent sale to Everlywell. Past investments include GoodRx (NASDAQ: GDRX), Payer Compass (acquired by Zelis Healthcare), Datassential (acquired by New Mountain), Net Health (acquired by The Carlyle Group), Verisys (acquired by Aperture Health), Membersy (now Kleers-Membersy), Passport Health Communications (acquired by Experian), and MedHOK (acquired by Hearst Health). This is Jeff\u2019s fifth year on the GrowthCap Top Healthcare Investors list.\u00a0<\/p>\n \u201cThe founders we back are taking on some of the hardest, most entrenched problems in healthcare. We\u2019re fortunate to act as partners in this important work.\u201d \u2014 Jeff Haywood<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Steve LeSieur<\/p>\n Firm: Spectrum Equity \u00a0<\/p>\n Steve LeSieur has co-led Spectrum Equity<\/a>\u2018s healthcare investing with Jeff Haywood since 2015, focusing on high-growth software and data services companies across the healthcare continuum.<\/p>\n Steve recently served on the board of GoodRx (NASDAQ: GDRX). Past investments include Payer Compass (acquired by Zelis Healthcare), Definitive Healthcare (NASDAQ: DH), MedHOK (acquired by Hearst Health), HealthMEDX (acquired by NetSmart), Passport Health Communications (acquired by Experian), and QTC Management (acquired by Lockheed Martin). This is Steve\u2019s fifth year on the GrowthCap Top Healthcare Investors list.<\/p>\n \u201cHealthcare has real stakes\u2014the companies we invest in are changing what care looks like for both patients and the people who deliver it. I\u2019m grateful to support their innovation.\u201d \u2014 Steve LeSieur<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Robbert Vorhoff<\/p>\n Firm: General Atlantic \u00a0<\/p>\n Robbert (Robb) Vorhoff is a Managing Director and the Global Head of Healthcare at General Atlantic (GA), where he leads the firm\u2019s healthcare investing strategy and serves on the Global Growth Equity Investment Committee. He has spent more than two decades at the firm and assumed the leadership role of GA\u2019s healthcare efforts in 2014.<\/p>\n Since 2014, Robb has led or co-led 23 new healthcare investments (excluding follow-ons), representing over $4 billion in capital deployed. Over the past two years (2024\u20132025), he has deployed over $1 billion across investments including Vi Labs, Eventus WholeHealth, US Urology, and Legent Health. He has also led major investments such as Alignment Healthcare, Landmark Health, and Oak Street Health, with a long-term thematic focus on value-based care, technology enablement to shift care from higher- to lower-cost settings, specialty Rx access and affordability, and innovative health system partnership models.<\/p>\n Under his leadership, GA\u2019s global healthcare investing team focuses on meaningful value creation, leveraging more than 80 value creation professionals to support portfolio companies across strategy, go-to-market, human capital, capital markets advisory, and M&A. He has delivered significant realized outcomes, including Alignment Healthcare (ALHC; $3.78 billion market cap), eviCore Healthcare ($3.6 billion acquisition by Express Scripts), Oak Street Health ($10.6 billion acquisition by CVS Health), Landmark Health (acquired by Optum Health), and OneOncology ($2.1 billion acquisition by Cencora and TPG).<\/p>\n \u201cI\u2019m honored to be recognized by GrowthCap and grateful to work alongside founders and management teams advancing innovation across healthcare. This recognition reflects General Atlantic\u2019s disciplined, long-term commitment to improving patient and community outcomes.\u201d \u2014 Robbert Vorhoff<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Ethan Liebermann<\/p>\n Firm: TA Associates \u00a0<\/p>\n Ethan Liebermann is a Managing Director at TA<\/a> and Head of the firm\u2019s North America Healthcare Group. Since joining TA in 2007, Ethan has been instrumental in building TA\u2019s healthcare platform, partnering with management teams to scale high-growth, mission-critical businesses across healthcare IT, life sciences, provider services, payor services, and specialty benefit managers.<\/p>\n Ethan currently serves on the Boards of Healthmark Group, Solarity, Aptarro, RLDatix, and Intelerad, all investments he led or co-sponsored. He previously served on the Boards of Aldevron, CCRM, IMA Medical Group, MedRisk, and SoftWriters.<\/p>\n Prior to TA, Ethan worked in the Global Healthcare Corporate and Investment Banking Group at Banc of America Securities. He received a BA in economics and biology from the University of Pennsylvania and an MBA from Harvard Business School.<\/p>\n \u201cHealthcare is evolving at an unprecedented pace, with automation and emerging technologies reshaping how care is delivered and managed. At TA, we are privileged to partner with leaders who combine deep domain expertise with a clear vision for building a more effective healthcare ecosystem. This recognition reflects the dedication of those teams and the collective effort across TA to help them scale with purpose and create lasting impact.\u201d \u2014 Ethan Liebermann<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Dr. Robert Mittendorff, MD<\/p>\n Firm: B Capital \u00a0<\/p>\n Dr. Robert Mittendorff is a General Partner and Global Head of Healthcare at B Capital, where he leads venture and growth investments in category-defining healthcare companies. At B Capital, he has invested in and serves on the board of companies such as CapitalRx, Carlsmed, Nalu Medical, Lively, Triumvira, Atomwise, and Carrick, among others.<\/p>\n Previously, Robert spent nearly a decade at Norwest Venture Partners as Partner and Co-Head of Healthcare. He has been involved in investments and associated exits with public equity value or acquisition value exceeding $10 billion. He is a board-certified emergency physician and former public company operating executive with experience spanning investing, complex business development transactions, the leadership of clinical advisory boards, product development, clinical trials, commercial activities, and clinical services management. He is a Fellow of the American Academy of Emergency Medicine (FAAEM).<\/p>\n Robert has extensive board experience as both a director and observer at companies including Impel Neuropharma, Avalyn Pharma, Qventus, VisitPay, TigerConnect, Neocis, Talkspace, Omada, Route92, Silk Road Medical (SILK), iCardiac (acq. by eResearch), Telcare (acq. by BioTelemetry), Intersect ENT (Nasdaq: XENT), and iRhythm Technologies (Nasdaq: IRTC).<\/p>\n Robert was involved with the initial investments in Misfit Wearables (acquired by Fossil) and Health Catalyst (HCAT), and led seed investments in Myome, Excision Biosciences, and Clerio.<\/p>\n Robert was co-chair of the Digital Healthcare Innovation Summit and a member of the Leadership Fellows at Johns Hopkins. Prior to his career in venture capital, he was an executive at Hansen Medical Inc., where he launched the Magellan & Sensei X robots and led the Company\u2019s partnerships with GE, Siemens, Philips, and St. Jude Medical.<\/p>\n He has worked in portfolio strategy at Merck, as a management consultant at BCG, and as an emergency physician at Kaiser Permanente. He earned an MD from Harvard Medical School, trained in Emergency Medicine at Stanford University, and earned an MBA from Harvard Business School and a BS in biomedical engineering from Johns Hopkins University. Robert has completed fellowships with Howard Hughes, MIT, and HBS. He is based in San Francisco.<\/p>\n \u201cHealthcare\u2019s transformation is accelerating and we\u2019re seeing a new generation of companies delivering real clinical impact alongside durable business models. At B Capital, we remain focused on the convergence of artificial intelligence and the engineering of chemistry and biology as forces reshaping drug discovery, care delivery, and patient outcomes. This recognition reflects the incredible work of our team, and I\u2019m energized to keep partnering with the entrepreneurs who are defining what healthcare looks like next.\u201d \u2014 Dr. Robert Mittendorff, MD<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Garheng Kong<\/p>\n Firm: HealthQuest Capital \u00a0<\/p>\n A physician, scientist, and engineer by training, Garheng Kong has over two decades of experience investing in innovative companies in all areas of healthcare and has led over 40 companies to successful exits (IPO and M&A).\u00a0<\/p>\n Garheng is the Managing Partner and Founder of HealthQuest Capital<\/a>, a private asset firm that currently provides growth capital to transformative companies that are improving value in the healthcare system. Prior to founding HealthQuest, Garheng was a partner at Intersouth Partners and Sofinnova Investments, and has also spent time at GlaxoSmithKline and McKinsey, and as a CEO of two healthcare companies.\u00a0<\/p>\n Garheng also serves as Lead Director of LabCorp (LH) and on the boards of Smith & Nephew PLC (SNN), Xeris Biopharma Holdings (XERS), IKS Health (NSE: IKS), Duke University Health System, Duke University Board of Trustees, Dell Children\u2019s Foundation, UT Medicine, UT President\u2019s Commercial Advisory Board, and the Austin Healthcare Council Board. He is an Aspen Institute Health Innovators Fellow, Kauffman Fellows Mentor, and member of YPO.\u00a0<\/p>\n Garheng received undergraduate degrees in both chemical engineering and biological sciences from Stanford, while on an athletic scholarship, and earned MD, PhD, and MBA degrees from Duke University.<\/p>\n \u201cI\u2019m honored to be recognized as a Top Healthcare Investor for 2026. Healthcare is complex and constantly evolving, and we approach it with a deep sense of responsibility to patients, providers, and the broader system. This acknowledgment reflects the strength of our team and the founders we\u2019re privileged to support. They are building durable companies that address real gaps in care and create lasting value. We\u2019re grateful for the trust they place in us and remain committed to backing businesses that combine strong fundamentals with meaningful impact.\u201d \u2014 Garheng Kong<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Joshua Nelson<\/p>\n Firm: THL Partners \u00a0<\/p>\n Joshua Nelson is a senior leader at THL<\/a>, where he heads the firm\u2019s healthcare vertical and serves on both the Operating Committee and Investment Committee.<\/p>\n A driving force behind the expansion of THL\u2019s healthcare franchise, Josh has played a central role in shaping the firm\u2019s Identified Sector Opportunities (ISOs) in areas such as pharma services, bioprocessing, and healthcare IT. Over the past decade, he has built and led a dedicated team of investment professionals and executive partners, while cultivating a deep bench of external advisors. His strategic vision and firmwide leadership have been instrumental in establishing THL as a market leader across these dynamic sectors.<\/p>\n Josh is currently a director of Adare Pharma Solutions, Agiliti, CSafe Global, Hospice Care Holdings, Headlands Research, IMO Health, Red Nucleus, Senior Home Care Holdings, and Smile Doctors. His prior directorships include 1-800 CONTACTS, Inc., Curo Health Services, Hawkeye Energy Holdings, Healthcare Staffing Services, Intermedix Corporation, Nextech, Party City, and Syneos Health (formerly inVentiv Health, Inc.).<\/p>\n \u201cPartnering with visionary companies that are improving the way care is delivered\u2014that\u2019s what energizes me. We are proud to help these companies grow and make a lasting impact on the patients and providers they serve.\u201d \u2014 Joshua Nelson<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Megan Preiner<\/p>\n Firm: THL Partners \u00a0<\/p>\n As a Managing Director in THL<\/a>\u2019s Healthcare vertical, Megan Preiner focuses on the firm\u2019s Identified Sector Opportunities (ISOs) in healthcare services, including pharma services, bioprocessing, and home-based care. Over the past decade, she has assembled a team of investment professionals and executive partners, and a robust network of third-party advisors, to establish the firm\u2019s industry-leading franchise in these areas.<\/p>\n Megan plays a pivotal role within THL\u2019s broader healthcare investment team, where she is respected not just for her sharp investment acumen and operational expertise, but also for her dedication to developing talent. She has guided and influenced the careers of many rising professionals, reinforcing the firm\u2019s strong tradition of excellence and forward-thinking leadership.<\/p>\n Megan is currently a director for several healthcare organizations, including Adare Pharma Solutions, Agiliti, Headlands Research, Ingenovis, Red Nucleus, Senior Home Care Holdings, and Smile Doctors. Her prior directorships include CSafe Global and Intermedix Corporation.<\/p>\n \u201cHealthcare is evolving rapidly, and we\u2019re fortunate to work with companies that are leading the charge. From tech-enabled services to smarter care models, the impact is both meaningful and measurable.\u201d \u2014 Megan Preiner<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Alex Albert<\/p>\n Firm: TPG \u00a0<\/p>\n Alex Albert is a Partner at TPG based in San Francisco, where he co-leads healthcare investing for TPG Capital, the firm\u2019s US and European private equity business. He has served on the boards of several leading healthcare organizations across a variety of sectors, including Hanger, Radius Health, Summit BHC, Duly Health and Care, National Veterinary Associates, OB Hospitalist Group, Unified Women\u2019s Healthcare, and Jazz Pharmaceuticals. Albert is a former member and Chairperson of the board of directors of the Healthcare Private Equity Association.<\/p>\n Prior to joining TPG in 2025, Alex served as a Founding Partner at Patient Square Capital after serving as Partner and Co-Head of Healthcare Private Equity at Ares Management. Earlier in his career, he was a Vice President at FFL Partners and focused on healthcare private equity investments at KKR. Alex holds a master\u2019s degree in quantitative methods from Columbia University, a master\u2019s degree in economics from the University of Oxford, and a bachelor\u2019s degree in economics from Vanderbilt University.<\/p>\n \u201cTPG\u2019s healthcare investing approach is rooted in long-standing conviction around supporting the growth of companies delivering life-enhancing scientific and technological innovations that enable high-quality, accessible, and value-centric care. The firm has been investing behind these themes for decades, and we are proud to partner with excellent management teams that deliver breakthrough innovations to enable a more effective, patient-focused, and integrated healthcare system.\u201d \u2014 Alex Albert<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Dr. John W. Lin, MD<\/p>\n Firm: TPG \u00a0<\/p>\n Dr. John W. Lin, MD, is a Partner at TPG based in San Francisco, where he focuses on healthcare investments for TPG Capital, the firm\u2019s US and European private equity business. John has spent his entire career in healthcare, first as a surgeon, then in corporate healthcare leadership and strategy roles, and ultimately in investing. Since joining TPG as an operations leader in 2019, John has leveraged his clinical and operational expertise to help lead complex transactions and portfolio value creation initiatives.<\/p>\n Prior to TPG, John oversaw global strategy at GE Healthcare, where he was responsible for leading strategic initiatives at the corporate and business unit levels, including capital allocation, profitable growth, and active portfolio management. Before GE, John was a Partner at McKinsey & Company focused on healthcare and higher education. John trained in general surgery at the Johns Hopkins Medical Institutions and has conducted research in gastrointestinal cancer and pancreatic embryology. He holds an MD degree from Johns Hopkins University School of Medicine as well as bachelor\u2019s and master\u2019s degrees from Massachusetts Institute of Technology.<\/p>\n \u201cTPG\u2019s approach to healthcare investing is built upon decades of experience partnering with leaders in healthcare that are advancing innovation, expanding access, and delivering better care at lower cost. Working closely with management teams, TPG brings deep sector experience and proven operational expertise to help our companies navigate an increasingly complex healthcare environment and build durable businesses centered around patients and their healthcare providers.\u201d \u2014 Dr. John W. Lin, MD<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Chris Adams<\/p>\n Firm: Francisco Partners \u00a0<\/p>\n Chris Adams is a Partner at Francisco Partners<\/a>, a senior member of the firm\u2019s healthcare IT investing team, and serves on the firm\u2019s investment committee. He focuses on healthcare technology investments, with deep expertise across pharmacy, payer-facing software, information-enabled services, and technology-enabled services. Since joining FP in 2008, Chris has played a leadership role in building and scaling several of the firm\u2019s most successful healthcare investments.<\/p>\n Chris is known for his ability to identify category-defining platforms early, work closely with management teams, and drive sustained value creation through strategic focus, operational discipline, and thoughtful M&A. He has led complex transactions across carve-outs, founder-led businesses, and scaled healthcare platforms embedded deeply within mission-critical workflows. Across these investments, Chris has consistently demonstrated strong judgment around market structure, regulatory dynamics, and long-term customer value.<\/p>\n Chris currently serves on the boards of ANDHealth, GoodRx, and RedSail, and has previously served on the boards of Aesynt, Availity, Capsule, CoverMyMeds, Landmark Health, QuadraMed, TRC Healthcare, and Trellis Rx.<\/p>\n \u201cThis recognition reflects the strength of the team we\u2019ve built at Francisco Partners\u2014both on the investment side and across our operating executives, who are critical partners in building and scaling durable healthcare platforms. We\u2019ve been fortunate to work closely with management teams focused on expanding access, improving adherence, and lowering costs while supporting high-quality healthcare. Seeing those efforts translate into better outcomes for patients and the broader healthcare system is what makes the work meaningful.\u201d \u2014 Chris Adams<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Matt Emery<\/p>\n Firm: JMI Equity \u00a0<\/p>\n Matt Emery joined JMI<\/a> in 2006 and focuses on JMI\u2019s investments in high-potential software and AI-driven companies, including healthcare IT businesses. Matt has held numerous board positions at JMI portfolio companies during his tenure and currently oversees the investments or serves on the boards of Boulevard, CipherHealth, Clio, Jane Software, Parachute Health, PointClickCare, and TimelyCare. He played an active role with investments in Axonify (acquired by Luminate Capital Partners), Capsule Tech (acquired by Qualcomm), Healthx (acquired by Zipari), Navicure (acquired by Bain Capital), and Workfront (acquired by Adobe).<\/p>\n Prior to JMI, Matt was an analyst in the technology investment banking group at Thomas Weisel Partners and a research associate at Thompson, Siegel & Walmsley. Matt is a CFA charterholder and graduated from the University of Virginia with a BS in commerce.<\/p>\n \u201cWe\u2019re in the most consequential period I\u2019ve ever seen in healthcare investing. AI is fundamentally changing what\u2019s possible in healthcare \u2013 not just automating tasks but enabling care teams to operate at a level of effectiveness that wasn\u2019t achievable before. The companies that earn the right to lead their categories over the next decade will be the ones that embed these capabilities into the core of how care gets delivered. Partnering with founders and management teams \u2013 and earning the right to be the most valuable partner they\u2019ve ever had \u2013 is what drives me every day.\u201d \u2014 Matt Emery<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Laura Veroneau<\/p>\n Firm: Optum Ventures \u00a0<\/p>\n Laura\u2019s experience, which ranges from a healthcare startup to UnitedHealth Group, CVS Health, and Transformation Capital, has enabled Laura to develop a deep understanding of the healthcare system with an eye on how innovation can integrate into and transform the overall industry.\u00a0<\/p>\n Laura received her undergraduate degree in economics and legal studies from Williams College, received an MBA from the MIT Sloan School of Management, and currently sits on the Board of Overseers for Brigham and Women\u2019s Hospital.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Thomas Tarnowski<\/p>\n Firm: Summit Partners \u00a0<\/p>\n Thomas Tarnowski is a Managing Director on the Summit Partners<\/a> Healthcare & Life Sciences team. Since joining the firm\u2019s London office in 2013, Thomas has played a central role in building and expanding the firm\u2019s healthcare practice in Europe, helping establish Summit Partners as a leading growth equity investor in healthcare services and life sciences across the region.<\/p>\n Over the course of his tenure, Thomas has developed deep experience in value-based care models, multi-site physician-led healthcare platforms, and technology-enabled healthcare and life sciences solutions. He has led investments in 12 companies representing more than $735 million in invested capital. His board and investment experience includes Advance Medical (acquired by Teladoc), CluePoints (recapitalized with EQT), DentalPro (acquired by BC Partners), Deine Urologie, DERMANOVIS, Dreampath Diagnostics, Independent Vetcare (acquired by EQT), RadioOnkologieNetzwerk (acquired by Medipass), Viroclinics Biosciences (acquired by Cerba Healthcare), and zahneins (acquired by PAI Partners).<\/p>\n Thomas holds an MBA from Harvard Business School and a BBA in finance from Valdosta State University.<\/p>\n \u201cAt Summit, we\u2019re focused on partnering with healthcare companies that aim to enhance value to patients, providers, and payors. It\u2019s a privilege to support leadership teams who are working to modernize care delivery and improve access, outcomes, and quality in a complex, evolving landscape.\u201d \u2014 Thomas Tarnowski<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Jono Pagden<\/p>\n Firm: Summit Partners \u00a0<\/p>\n Jono Pagden is a Partner on the Healthcare & Life Sciences team at Summit Partners<\/a>. Based in London, Jono focuses on partnering with healthcare services, diagnostics, and life sciences tools and technology companies in Europe, bringing deep experience across technology-enabled healthcare and specialist care businesses operating in complex, regulated markets.<\/p>\n Since joining Summit in 2016, Jono has played a key role in multiple healthcare investments spanning specialist care delivery, multi-site services, clinical trial software and laboratory technology. His investment and board experience includes Advance Medical (acquired by Teladoc), CluePoints (recapitalized by EQT), Deine Urologie, DERMANOVIS, Dreampath Diagnostics, Fortis Life Sciences and zahneins (acquired by PAI Partners).<\/p>\n Jono holds a Bachelor of Business Science, with honors, in accounting and finance from the University of Cape Town. He is a dual British and South African national.<\/p>\n \u201cIt\u2019s a privilege to partner with executives and operators who are working to advance how healthcare is accessed and delivered. I\u2019m proud to support their efforts to help scale businesses that we believe generate meaningful improvements across the sector.\u201d \u2014 Jono Pagden<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Ben Levin<\/p>\n Firm: Level Equity \u00a0<\/p>\n Ben Levin is a Co-Founder and the Chief Executive Officer of Level Equity<\/a>. He has been an investor in rapidly growing private companies since 1997 and one of the first institutional investors in numerous category-defining software businesses, dozens of which have achieved successful exits and several of which have scaled to over $100 million in revenues.\u00a0<\/p>\n Ben co-founded Level with the desire to create an amazing culture and capitalize on emerging gaps in software growth investing. Level currently manages over $6.4 billion, has made over 125 growth investments, and achieved over 70 liquidity events. Ben aspires to connect deeply with founders and management teams of high-growth software businesses, aiming to meet them where they are and to provide them with the necessary capital and value creation resources to scale their businesses. He has spent his career sourcing and executing investments in great software companies and helping to enhance their value over time as they chase amazing outcomes.<\/p>\n \u201cIt\u2019s always flattering to be recognized by GrowthCap for this work we love to do. We have increased our focus on the amazing software business models that are animating change in the evolving healthcare market. Partnering with companies that are helping modernize critical systems and improve patient and provider experiences is exciting and meaningful work. We are fortunate to get the opportunity to partner with the founders and managers who are running them.\u201d \u2014 Ben Levin<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Matt Carroll<\/p>\n Firm: WestView Capital Partners \u00a0<\/p>\n Since WestView<\/a>\u2019s founding in 2004, Matt Carroll has led the firm\u2019s healthcare technology and outsourced services investment strategy, building one of WestView\u2019s core industry verticals. He focuses on partnering with founder- and management-led businesses serving the healthcare provider and payor markets, with particular emphasis on revenue cycle management, payer cost containment, and outsourced administrative services. Matt has led investments in Executive Health Resources, eSolutions, Xtend Healthcare, Alpha II \/ Aptarro, Jopari Solutions, The Phia Group, and RSiRCM, working closely with management teams to scale infrastructure, pursue strategic acquisitions, and drive long-term value creation. Many of these companies have gone on to become market leaders and enduring participants in their industry subsector.<\/p>\n Prior to WestView, Matt served as Head of Corporate Development at LogistiCare, a leading medical transportation cost containment provider to the healthcare payor market, where he led growth initiatives and M&A activity. Earlier in his career, he was an Associate at Triumph Capital and an Analyst in the Private Capital Group at Dean Witter Reynolds. Matt earned a BS in finance, magna cum laude, from Boston College.<\/p>\n \u201cEarly in my career, I was fortunate to see firsthand how complexity, technology deficiency, payer\/provider friction, and regulatory change create real and consistent challenges across the healthcare system. As a result, I\u2019ve focused my investing efforts on partnering with management teams who are building solutions that help payors and providers operate more efficiently, drive administrative simplification in the claims process, make better operational, clinical and financial decisions, and ultimately to deliver better, more cost-effective patient outcomes as a result. Whether through technology, data, or tech-enabled knowledge expert services, our goal has been to support companies that streamline processes and bring greater transparency and accountability to healthcare. At WestView, we\u2019ve maintained a deep and consistent commitment to the healthcare sector. We\u2019re proud to work alongside entrepreneurs and executives to build scalable, market-leading businesses that create lasting value, not only for shareholders, but for the broader healthcare ecosystem.\u201d \u2014 Matt Carroll<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Dr. Arsani William, MD<\/p>\n Firm: Logos Global Management \u00a0<\/p>\n Dr. Arsani William is the Founder and Chief Investment Officer of Logos Global Management, a biotechnology-focused investment firm dedicated to identifying and investing in companies developing transformative medicines. Logos manages a public investment strategy alongside a series of closed-end investment vehicles supporting both public and private biotechnology companies advancing innovative therapeutics.<\/p>\n Arsani brings a distinctive perspective to investing, combining formal medical training with more than a decade of experience analyzing biotechnology companies, clinical trial design, and drug-development programs. His investment philosophy integrates deep biological insight, rigorous clinical trial statistics, and capital markets expertise, allowing Logos to identify opportunities where scientific complexity leads to market mispricing and asymmetric investment opportunities.<\/p>\n Arsani began his training in drug discovery and translational medicine as an undergraduate researcher at Stanford University. He later earned his MD from Harvard Medical School as a Gerald S. Foster Scholar and his MBA from Stanford Graduate School of Business.<\/p>\n Over his career, Arsani has led investments in more than 300 biotechnology companies across public and private markets. He serves on the boards of several biotechnology companies and is actively involved in various teaching and academic initiatives.<\/p>\n \u201cBiology remains the most powerful frontier of innovation in the world. As artificial intelligence begins to decode the complexity of human biology, the convergence of science, medicine, and capital creates an unprecedented opportunity; not only to generate exceptional returns, but to fundamentally change the trajectory of human health.\u201d \u2013 Dr. Arsani William, MD<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Adam Feinstein<\/p>\n Firm: Vesey Street Capital Partners \u00a0<\/p>\n Adam Feinstein is the Founder and Managing Partner of Vesey Street Capital Partners (VSCP) with over 30 years of investment experience exclusively in healthcare services. VSCP is a healthcare services private equity firm focused exclusively on lower middle market buyouts. The firm partners with the founders as the first private equity investor in a company and is also focused on corporate carve-outs. Before founding VSCP, he held leadership roles on Wall Street and in the healthcare industry. He was Senior Vice President of Corporate Development, Strategic Investments, and Office of the CEO at LabCorp, following a successful career as a Managing Director at Lehman Brothers\/Barclays Capital, where he focused on the healthcare industry.<\/p>\n As Chairman of VSCP\u2019s Investment Committee, Mr. Feinstein actively works with portfolio company executives, sources new investment opportunities, and oversees all firm activities. He serves on numerous boards \u2013 Inceptua, Shemmassian Academic Consulting, ComplexCare Solutions, AirSculpt Technologies (NASDAQ: AIRS), ScribeAmerica, Safecor Health, GastroMD, and PathGroup. Previously, he served on the boards of QualityMetric, Imedex, and Surgery Partners (NASDAQ: SGRY).<\/p>\n Mr. Feinstein\u2019s industry influence stems from the deep relationships he built at Lehman Brothers and LabCorp. As a CFA charterholder, he holds a BS in business from the Smith School at the University of Maryland and was part of the inaugural class of Nashville\u2019s Healthcare Council Fellows program. He also created the Vesey Street Capital Partners Foundation to support charitable organizations including NYU Langone Medical Center, La Scala Opera, USTA Foundation, Tennis Hall of Fame, New York Food Bank, National Holocaust Museum, Metropolitan Museum of Art, and many additional charities.<\/p>\n \u201cThe greatest lesson that I have learned from investing in the healthcare services industry for over 30 years is that exceptional management teams are one of the key reasons for success. Most healthcare services businesses are not proprietary, so it really comes down to the people running the business. Vesey Street Capital Partners identifies great industry operators, and we partner with them to execute on a strategy to create significant value for our investors.\u201d \u2014 Adam Feinstein<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Tadd Wessel<\/p>\n Firm: Petrichor Healthcare Capital Management \u00a0<\/p>\n Tadd Wessel is the Founder and Managing Partner of Petrichor, a private equity firm focused on healthcare. He is also a Founder and Managing Partner of Scion Life Sciences, an affiliate of Petrichor. Tadd has more than 25 years of experience, primarily focused on investing and building companies in the life sciences sectors.\u00a0<\/p>\n 2025 was a banner year for Petrichor\u2019s inaugural fund, with six exits and the top performing stock on the XBI (SPDR S&P Biotech ETF), Palvella Therapeutics (NASDAQ: PVLA).\u00a0<\/p>\n Previously, he was a Partner at OrbiMed Advisors. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group. Tadd began his career in the life sciences investment banking groups at Citigroup and Robertson Stephens.\u00a0<\/p>\n Tadd has served on more than 35 boards, most recently including Aurion Biotech (private), Cryoport (NASDAQ: CYRX), ITM Isotope Technology Munich (private), and Palvella Therapeutics (NASDAQ: PVLA). He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. He also serves on the board of the ICPO Foundation, whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally.\u00a0<\/p>\n Tadd holds an AB in biology from Princeton University.\u00a0<\/p>\n \u201cWith innovation in life sciences at all-time highs, we believe this is one of the most exciting periods to be investing in the sector. Our team has been together for more than 15 years, partnering with companies that are shaping the future of medicine. Helping bring transformative therapies to patients \u2014 from radiopharmaceuticals like Pluvicto for prostate cancer to cell therapies such as Vyznova for corneal endothelial disease \u2014 is both a privilege and what makes this work so meaningful.\u201d \u2014 Tadd Wessel<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Prateesh Maheshwari<\/p>\n Firm: Maverick Ventures \u00a0<\/p>\n Prateesh Maheshwari joined Maverick in 2018 and focuses on investing at the intersection of healthcare and technology. At Maverick, he partners with founders building innovative companies that improve the delivery, accessibility, and economics of healthcare. He has led and supported investments in businesses such as Belong Health, CareHarmony, Chapter, and Garner, which are reimagining how care is delivered and paid for across the healthcare system.<\/p>\n Prior to Maverick, Prateesh was one of the first employees at Oscar Health (NYSE: OSCR), where he served as Director of Finance & Strategy. At Oscar, he worked across a range of strategic initiatives including insurance plan pricing and design, geographic expansion, and supporting company financings as the business scaled nationally. Prateesh began his career at Bain Capital Credit, where he focused on investments primarily in high yield and distressed credit.<\/p>\n He holds a BS in economics from the Wharton School at the University of Pennsylvania (summa cum laude) and an MBA with distinction from Harvard Business School. Prateesh currently serves on the boards of several private healthcare companies and Operation Access, a nonprofit focused on improving healthcare access.<\/p>\n \u201cWe consider ourselves lucky to work alongside world class founders who are focused on the Triple Aim in healthcare. It\u2019s a privilege to play a small part in the journey of these founders and their companies as they work to transform healthcare.\u201d \u2014 Prateesh Maheshwari<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Robert Heimann<\/p>\n Firm: RC Capital \u00a0<\/p>\n In his role as a Managing Partner, Rob Heimann leads RC Capital (RCC)\u2019s healthcare services practice, partnering with founders who share a patient- and provider-centric philosophy dedicated to delivering better outcomes, improving patient access, lowering the cost of care, and delivering preferred platforms for providers to practice.<\/p>\n Rob serves as a member of the Board of Directors of the Christ Hospital Health Network and The Christ Hospital College of Nursing. He also serves as an Alternative Investment Advisor to Cincinnati Children\u2019s Hospital Medical Center. In addition, he serves on the board of the Elizabeth Gamble Deaconess Home Association, a foundation dedicated to improving healthcare services. He is currently a member of the boards of CRC, AlignedCardio, and EPP. Rob served as a board member at FlexCare Infusion Centers (sold to a confidential strategic), Label Insight (sold to Nielsen), PerfectServe (sold to K1), MedPlast (sold to Water Street and JLL Partners), invivodata (sold to ERT), Lattice Engines (sold to Dunn & Bradstreet), Building Engines (sold to JLL), Trax Technologies (sold to Strattam Capital), and observer to the board of MX Logic (sold to McAfee).<\/p>\n Rob joined RCC in early 2004 with operations and investment experience in PE-backed companies with particular expertise in M&A transactions, channel development, and corporate strategy. Rob holds an MBA from the Kellogg School of Management at Northwestern University, where he graduated with distinction. He holds a BS from the University of Virginia.<\/p>\n \u201cHealthcare transformation requires more than capital; it demands partnership. For three decades, RC Capital has supported founders reshaping care models to drive quality, efficiency, and accessibility. Witnessing the real impact on healthcare for providers and patients has been a privilege.\u201d \u2014 Rob Heimann<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Carter McNabb<\/p>\n Firm: RC Capital \u00a0<\/p>\n Carter McNabb is Managing Partner at RC Capital (RCC), where he leads the firm\u2019s medical technology investing practice and has been central to building its healthcare strategy and reputation within the medical device sector. Since joining RCC in 1999, he has partnered with founders and management teams to scale innovative technologies that improve clinical outcomes and patient care.<\/p>\n Prior to RCC, Carter worked in marketing and business development at Home Technology Healthcare, a private equity-backed home healthcare platform later acquired by Integrated Health Services. As a Bradford Fellow, he also worked in equity research at J.C. Bradford & Co. while earning his MBA from Vanderbilt University.<\/p>\n Carter has achieved numerous highly profitable exits in healthcare services and medical technology, including Suros Surgical Systems (acquired by Hologic), Bolder Surgical (acquired by Hologic), Accelecare (acquired by Revelstoke), SurgiQuest (acquired by CONMED), NICO (acquired by Stryker), OrthoHelix (acquired by Tornier), Invivodata (acquired by ERT), PerfectServe (acquired by K1), TissueTech (majority recap by EssexWoodlands), Standard Bariatrics (acquired by Teleflex), OMNIA (majority recap by Leonard Green & Partners), and Orthoscan (acquired by ATON). Carter is also an independent board member of UC Health, the largest academic medical center in Southwest Ohio.<\/p>\n He holds a BA in classical studies from Trinity College and an MBA from Vanderbilt University.<\/p>\n \u201cFor over thirty years, RC Capital has partnered with healthcare entrepreneurs to improve outcomes, expand access, and lower costs. We take a hands-on approach to building strong, sustainable businesses that make a real difference for patients and providers.\u201d \u2014 Carter McNabb<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Sujit Banerjee<\/p>\n Firm: K1 Investment Management \u00a0<\/p>\n Sujit Banerjee is a Managing Director at K1 Investment Management, one of the largest investors in small-cap AI-powered software. Headquartered in Manhattan Beach, California, K1 seeks to partner early with founders and management teams to build AI-powered, mission-critical systems of record for enterprise clients globally\u2014and Sujit brings that partnership model to enterprise software companies across a range of industries and workflows.<\/p>\n Across a diverse portfolio, Sujit works closely with executive teams to refine product strategy, expand enterprise relationships, and pursue targeted M&A\u2014with a consistent focus on embedding AI and automation into the workflows that organizations depend on daily.<\/p>\n Among his partnerships, Sujit leads K1\u2019s investment in PerfectServe, a clinical communication and collaboration platform used by hospitals and health systems nationwide. Throughout the partnership, Sujit has worked alongside the PerfectServe team to support AI-driven workflow automation initiatives and the platform\u2019s continued growth as a mission-critical tool embedded in daily clinical operations.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Dr. Kapila Ratnam<\/p>\n Firm: NewSpring Capital \u00a0<\/p>\n
Title: Managing Director and Co-Head of Spectrum Healthcare Investing<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Steve-LeSieur-Spectrum-Website.png\"\/)
<\/p>\n
Title: Managing Director and Global Head of Healthcare<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Robb-Vorhoff-General-Atlantic.png\"\/)
<\/p>\n
Title: Managing Director and Head of TA\u2019s North America Healthcare Group<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Ethan-Liebermann-TA-Associates.png\"\/)
<\/p>\n
Title: General Partner and Global Head of Healthcare<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Robert-Mittendorff-MD-B-Capital.png\"\/)
<\/p>\n
Title: Managing Partner and Founder<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Garheng-Kong-HealthQuest.png\"\/)
<\/p>\n
Title: Managing Director and Head of Healthcare<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Joshua-Nelson-THL.png\"\/)
<\/p>\n
Title: Managing Director<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Megan-Preiner-THL.png\"\/)
<\/p>\n
Title: Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Alex-Albert-TPG.png\"\/)
<\/p>\n
Title: Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/John-Lin-TPG.png\"\/)
<\/p>\n
Title: Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Chris-Adams-Francisco-Partners.png\"\/)
<\/p>\n
Title: Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Matt-Emery-JMI.png\"\/)
<\/p>\n
Title: Managing Partner and Founding Team Member<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Laura-Veroneau-Optum-Ventures.png\"\/)
Laura Veroneau is a Managing Partner and founding team member of Optum Ventures. Under Laura\u2019s guidance and leadership, Optum Ventures has gained recognition as a leading platform in healthcare investing \u2014 now with 65+ portfolio companies and over $2 billion in assets under management.<\/p>\n
Title: Managing Director<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Thomas-Tarnowski-Summit-Partners.png\"\/)
<\/p>\n
Title: Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Jono-Pagden-Summit-Partners.png\"\/)
<\/p>\n
Title: Co-Founder and Chief Executive Officer<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Ben-Levin-Level-Equity.png\"\/)
<\/p>\n
Title: Managing Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Matt-Carroll-WestView.jpg\"\/)
<\/p>\n
Title: Founder and Chief Investment Officer<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Arsani-William-Logos-Capital.png\"\/)
<\/p>\n
Title: Founder and Managing Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Adam-Feinstein-Vesey-Street.png\"\/)
<\/p>\n
Title: Founder and Managing Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Tadd-Wessel-Petrichor.png\"\/)
<\/p>\n
Title: Managing Director<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Prateesh-Maheshwari-Maverick-Ventures.png\"\/)
<\/p>\n
Title: Managing Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Rob-Heimann-RC-Capital.png\"\/)
<\/p>\n
Title: Managing Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Carter-McNabb-RC-Capital.png\"\/)
<\/p>\n
Title: Managing Director<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Sujit-Banerjee-K1.png\"\/)
<\/p>\n
Title: General Partner<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Kapila-Ratnam-NewSpring.png\"\/)
<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Martin-Felsenthal-Health-Velocity-Capital.png\"\/)
<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Kapil-Desai-Catalyst-Investors.png\"\/)
<\/p>\n